David W Haas1,2, Yoninah S Cramer3,4, Catherine Godfrey5, Susan L Rosenkranz3,4, Francesca Aweeka6, Baiba Berzins7, Robert Coombs8, Kristine Coughlin9, Laura E Moran10, David Gingrich6, Carmen D Zorrilla11, Paxton Baker12, Susan E Cohn7, Kimberly K Scarsi13. 1. Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee. 2. Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee. 3. Harvard TH Chan School of Public Health, Boston, Massachusetts. 4. Frontier Science Foundation, Brookline, Massachusetts. 5. Division of AIDS, National Institutions of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland. 6. Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California. 7. Division of Infectious Diseases, Northwestern University, Chicago, Illinois. 8. Departments of Medicine and Laboratory Medicine, University of Washington, Seattle, Washington. 9. Frontier Science & Technology Research Foundation, Inc, Amherst, New York. 10. Social & Scientific Systems, Silver Spring, Maryland, USA. 11. Department of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico. 12. Vanderbilt University Medical Center, Nashville, Tennessee. 13. Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Abstract
OBJECTIVE: In AIDS Clinical Trials Group study A5316, efavirenz lowered plasma concentrations of etonogestrel and ethinyl estradiol, given as a vaginal ring, while atazanavir/ritonavir increased etonogestrel and lowered ethinyl estradiol concentrations. We characterized the pharmacogenetics of these interactions. METHODS: In A5316, women with HIV enrolled into control (no antiretrovirals), efavirenz [600 mg daily with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)], and atazanavir/ritonavir (300/100 mg daily with NRTIs) groups. On day 0, a vaginal ring was inserted, releasing etonogestrel/ethinyl estradiol 120/15 μg/day. Intensive plasma sampling for antiretrovirals was obtained on days 0 and 21, and single samples for etonogestrel and ethinyl estradiol on days 7, 14, and 21. Seventeen genetic polymorphisms were analyzed. RESULTS: The 72 participants in this analysis included 25, 24 and 23 in the control, efavirenz, and atazanavir/ritonavir groups, respectively. At day 21 in the efavirenz group, CYP2B6 genotype was associated with increased plasma efavirenz exposure (P = 3.2 × 10), decreased plasma concentrations of etonogestrel (P = 1.7 × 10), and decreased ethinyl estradiol (P = 6.7 × 10). Compared to controls, efavirenz reduced median etonogestrel concentrations by at least 93% in CYP2B6 slow metabolizers versus approximately 75% in normal and intermediate metabolizers. Efavirenz reduced median ethinyl estradiol concentrations by 75% in CYP2B6 slow metabolizers versus approximately 41% in normal and intermediate metabolizers. CONCLUSION: CYP2B6 slow metabolizer genotype worsens the pharmacokinetic interaction of efavirenz with hormonal contraceptives administered by vaginal ring. Efavirenz dose reduction in CYP2B6 slow metabolizers may reduce, but will likely not eliminate, this interaction.
OBJECTIVE: In AIDS Clinical Trials Group study A5316, efavirenz lowered plasma concentrations of etonogestrel and ethinyl estradiol, given as a vaginal ring, while atazanavir/ritonavir increased etonogestrel and lowered ethinyl estradiol concentrations. We characterized the pharmacogenetics of these interactions. METHODS: In A5316, women with HIV enrolled into control (no antiretrovirals), efavirenz [600 mg daily with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)], and atazanavir/ritonavir (300/100 mg daily with NRTIs) groups. On day 0, a vaginal ring was inserted, releasing etonogestrel/ethinyl estradiol 120/15 μg/day. Intensive plasma sampling for antiretrovirals was obtained on days 0 and 21, and single samples for etonogestrel and ethinyl estradiol on days 7, 14, and 21. Seventeen genetic polymorphisms were analyzed. RESULTS: The 72 participants in this analysis included 25, 24 and 23 in the control, efavirenz, and atazanavir/ritonavir groups, respectively. At day 21 in the efavirenz group, CYP2B6 genotype was associated with increased plasma efavirenz exposure (P = 3.2 × 10), decreased plasma concentrations of etonogestrel (P = 1.7 × 10), and decreased ethinyl estradiol (P = 6.7 × 10). Compared to controls, efavirenz reduced median etonogestrel concentrations by at least 93% in CYP2B6 slow metabolizers versus approximately 75% in normal and intermediate metabolizers. Efavirenz reduced median ethinyl estradiol concentrations by 75% in CYP2B6 slow metabolizers versus approximately 41% in normal and intermediate metabolizers. CONCLUSION: CYP2B6 slow metabolizer genotype worsens the pharmacokinetic interaction of efavirenz with hormonal contraceptives administered by vaginal ring. Efavirenz dose reduction in CYP2B6 slow metabolizers may reduce, but will likely not eliminate, this interaction.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Nancy R Reynolds; Junfeng Sun; Haikady N Nagaraja; Allen L Gifford; Albert W Wu; Margaret A Chesney Journal: J Acquir Immune Defic Syndr Date: 2007-12-01 Impact factor: 3.731
Authors: Owain Roberts; Rajith K R Rajoli; David J Back; Andrew Owen; Kristin M Darin; Courtney V Fletcher; Mohammed Lamorde; Kimberly K Scarsi; Marco Siccardi Journal: J Antimicrob Chemother Date: 2018-04-01 Impact factor: 5.790
Authors: Carolina S Vieira; Maria V Bahamondes; Roberto M de Souza; Milena B Brito; Tatiana R Rocha Prandini; Eliana Amaral; Luis Bahamondes; Geraldo Duarte; Silvana M Quintana; Carolina Scaranari; Rui A Ferriani Journal: J Acquir Immune Defic Syndr Date: 2014-08-01 Impact factor: 3.731
Authors: Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas Journal: Clin Pharmacol Ther Date: 2019-07-05 Impact factor: 6.875
Authors: Daniel H Johnson; Charles Venuto; Marylyn D Ritchie; Gene D Morse; Eric S Daar; Paul J McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2014-04 Impact factor: 2.089
Authors: Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen Journal: J Antimicrob Chemother Date: 2008-02-14 Impact factor: 5.790
Authors: David W Haas; Awewura Kwara; Danielle M Richardson; Paxton Baker; Ioannis Papageorgiou; Edward P Acosta; Gene D Morse; Michael H Court Journal: J Antimicrob Chemother Date: 2014-04-11 Impact factor: 5.790
Authors: Kimberly K Scarsi; Kristin M Darin; Shadia Nakalema; David J Back; Pauline Byakika-Kibwika; Laura J Else; Sujan Dilly Penchala; Allan Buzibye; Susan E Cohn; Concepta Merry; Mohammed Lamorde Journal: Clin Infect Dis Date: 2015-12-08 Impact factor: 9.079
Authors: Brandon T Gufford; Ingrid F Metzger; Nadia O Bamfo; Eric A Benson; Andrea R Masters; Jessica Bo Li Lu; Zeruesenay Desta Journal: J Pharmacol Exp Ther Date: 2022-07-07 Impact factor: 4.402
Authors: David W Haas; Rosie Mngqibisa; Jose Francis; Helen McIlleron; Jennifer A Robinson; Michelle A Kendall; Paxton Baker; Sajeeda Mawlana; Sharlaa Badal-Faesen; Francis Angira; Ayotunde Omoz-Oarhe; Wadzanai P Samaneka; Paolo Denti; Susan E Cohn Journal: Pharmacogenet Genomics Date: 2022-01-01 Impact factor: 2.000